A novel mutation in SLC2A1 gene causing GLUT-1 deficiency syndrome in a young adult patient

Ala Üstyol¹, Satoru Takahashi², Halil Üğur Hatipoğlu¹, Mehmet Ali Duman¹, Murat Elevli¹, Hatice Nilgün Selçuk Duru¹

¹Department of Pediatrics, University of Health Sciences Haseki Training and Research Hospital, Istanbul, Turkey; ²Department of Pediatrics, Asahikawa Medical College, Asahikawa, Hokkaido, Japan. E-mail: alaustyol@gmail.com

Received: 25th July 2018, Revised: 17th September 2018, 26th November 2018, Accepted: 23rd January 2019

SUMMARY: Üstyol A, Takahashi S, Hatipoğlu HU, Duman MA, Elevli M, Selçuk Duru HN. A novel mutation in SLC2A1 gene causing GLUT-1 deficiency syndrome in a young adult patient. Turk J Pediatr 2019; 61: 946-948.

GLUT-1 deficiency syndrome is a rare, frequently unrecognized metabolic encephalopathy that is probably underdiagnosed. Although developmental delay, acquired microcephaly, spasticity, and impaired coordination were initially described as the classic findings, mild cases with no pronounced neuromotor compromise have since been included in the broad clinical spectrum with new mutations being identified more recently. We report a case of myoclonic seizures not responding to anti-epileptics since the age of one year in a 17-year-old patient with a normal phenotype and neuromotor development. Previously unreported p.Phe389Leu mutation was determined in the SLC2A1 gene in our patient. This case will be useful in clarifying the phenotype of GLUT-1 deficiency and reveals a new pathogenic mutation.

Key words: SLC2A1 gene, GLUT-1 deficiency syndrome, drug-resistant epilepsy.

Case Report

General information and clinical manifestations

Glucose provides energy for brain cells. Glucose transporter 1 (GLUT-1) is a membrane protein encoded by the SLC2A1 gene that plays a crucial role in glucose transport over the blood-brain barrier. The mutation in GLUT-1 known as GLUT-1 deficiency syndrome (GLUT-1 DS; OMIM #606777) is characterized by low levels of glucose in cerebrospinal fluid (CSF) despite normoglycemia.¹ GLUT-1 deficiency results in a range of symptoms that may exhibit significant variation from one patient to another. Approximately 150 GLUT cases have been reported, mainly from the USA, Europe and the East Asia.² To the best of our knowledge, our patient represents the second case of GLUT-1 DS from Turkey.

A 17-year-old male patient was born to healthy non-consanguineous parents after an uneventful pregnancy. Birth weight and head circumference were normal. The first infantile myoclonic seizure occurred at one year of age. Seizures continued at the same frequency and duration until the age of 17. The seizures did not respond to anticonvulsants, such as levetiracetam, carbamazepine or valproic acid. Cerebral magnetic resonance imaging (MRI) and electroencephalograms elicited no specific findings.

Laboratory tests

Laboratory tests revealed normal complete blood count and biochemistry. Lumbar puncture performed after 7-h fasting revealed a normal CSF glucose level in a normoglycemic setting (blood glucose, 93 mg/dl; CSF glucose 47mg/dl, and CSF to blood glucose ratio 0.50).
Genomic analysis

Genomic DNA was extracted from the patient’s and parents’ peripheral blood leukocyte was used as the template for polymerase chain reaction (PCR). Compatible primers were used to yield DNA fragments spanning the entire coding region and intron–exon boundaries of SLC2A1. A heterozygous missense mutation was determined in the SLC2A1 gene (c.1167C>A, Genebank accession no. NM_006516.2, p.Phe389Leu). Analysis of the parents confirmed that the SLC2A1 mutation had occurred de novo. Genomic DNAs of the proband’s father and mother exhibited wild type sequences (Fig. 1). The mutation was identified as potentially injurious by both PolyPhen-2 and SIFT.

Written informed consent for this report was obtained from the family.

Discussion

Our patient was followed-up due to antiepileptic-resistant epilepsy for several years. GLUT-1 DS was finally diagnosed at the age of 17. This syndrome is a rare, underdiagnosed encephalopathy. One possible reason for non-diagnosis or late diagnosis is that the high disease suspicion threshold means that diagnosis may only be considered with clinical findings such as developmental delay, acquired microcephaly, spasticity, and poor coordination in the years when it is first identified. Greater sharing of international data since the disease was first diagnosed means that increasing information is becoming available concerning the clinical spectrum of the mutation and the characteristic features of pathogenic mutations. Wide clinical variation has thus been revealed in patients carrying GLUT-1 mutation. This has particularly resulted in broader recognition of milder phenotypes. Our patient was normal in terms of phenotype and neuromotor development. Significant numbers (15%) of patients with a non-classical phenotype incorporating developmental delay and movement disorders have been observed among cases of Glut-1 DS. The spectrum of intellectual compromise may range from very severe to very mild.

Awareness of the broad range of potential clinical phenotypes associated with Glut-1 DS will facilitate earlier diagnosis of this treatable neurological condition.

The CSF to serum glucose ratio in GLUT-1 deficiency is characteristically low, under 40%. This ratio was recently reported at between 24% and 49%, with a mean value of approximately 37%, in one case series. Our patient’s CSF to serum glucose ratio was 50%, above this upper threshold. Our patient’s relatively high CSF to serum glucose ratio may explain the absence of classic findings and the isolated myoclonic seizures. However, this can only be confirmed through investigation of correlation between clinical findings and CSF to serum glucose ratios in larger patient series.

Previously unreported, de novo heterozygous missense mutation was determined in our patient. Although GLUT-1 deficiency was originally described as exhibiting an autosomal dominant pattern of inheritance, family
members have only been affected in 10% of case reports to date (autosomal dominant inheritance pattern), and approximately 90% have a de novo heterozygous mutation in SLC2A1. GLUT-1 mutations may take the form of missense, nonsense, frameshift, splice site, multiple exon deletion or complete gene deletion. Missense mutations constituted more than 40% of all mutations in two large series in the literature, and were the most prevalent mutation types. No characteristic mutation or phenotype-genotype correlation has been determined to date.

This syndrome has largely been seen in North America, Europe and East Asia. Our patient is the second genetically diagnosed case of GLUT-1 DS from Turkey. The other Turkish patient was a 7-year-old girl with a mutation (p.r126c) in the SLC2A1 gene.

Our patient was referred to another center to be started on a ketogenic diet and was placed under observation in terms of response to treatment.

Our case adds new phenotype findings of GLUT-1 deficiency to the literature and reveals a probable new pathogenic mutation. Although GLUT-1 deficiency is a rare condition, it should be considered in patients with drug-resistant epilepsy even with a normal phenotype and neuromotor development.

REFERENCES

1. Seidner G, Alvarez MG, Yeh JI, et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood–brain barrier hexose carrier. Nat Genet 1998; 18: 188-191.

2. Woo SB, Lee KH, Kang HC, Yang H, De Vivo DC, Kim SK. First report of glucose transporter 1 deficiency syndrome in Korea with a novel splice site mutation. Gene 2012; 506: 380-382.

3. Takahashi S, Ohinata J, Suzuki N, et al. Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures. Epilepsy Res 2008; 80: 18-22.

4. Leen WG, Klipper J, Verbeek MM, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 2010; 133: 655-670.

5. Pearson TS, Akman C, Hinton VJ, Engelstad K, De Vivo DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep 2013; 13: 342.

6. Ito Y, Takahashi S, Kagitani-Shimono K, et al. Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1 DS) in Japan. Brain Dev 2015; 37: 780-789.

7. Wang D, Pascual JM, Yang H, et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol 2005; 57: 111-118.

8. Yang H, Wang D, Engelstad K, et al. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann Neurol 2011; 70: 996-1005.

9. Gökben S, Yılmaz S, Klepper J, Serdaroglu G, Tekgül H. Video/EEG recording of myoclonic absences in GLUT1 deficiency syndrome with a hot-spot R126C mutation in the SLC2A1 gene. Epilepsy Behav 2011; 21: 200-202.